- Home
- MCRB vs TBI Comparison
MCRB vs TBI Comparison
Compare MCRB & TBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- TBI
- Stock Information
- Founded
- MCRB 2010
- TBI 1985
- Country
- MCRB United States
- TBI United States
- Employees
- MCRB N/A
- TBI N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- TBI Professional Services
- Sector
- MCRB Health Care
- TBI Consumer Discretionary
- Exchange
- MCRB Nasdaq
- TBI Nasdaq
- Market Cap
- MCRB 144.6M
- TBI 165.9M
- IPO Year
- MCRB 2015
- TBI 1996
- Fundamental
- Price
- MCRB $17.75
- TBI $5.73
- Analyst Decision
- MCRB Hold
- TBI Buy
- Analyst Count
- MCRB 4
- TBI 1
- Target Price
- MCRB $14.33
- TBI $8.00
- AVG Volume (30 Days)
- MCRB 101.5K
- TBI 266.6K
- Earning Date
- MCRB 11-12-2025
- TBI 11-03-2025
- Dividend Yield
- MCRB N/A
- TBI N/A
- EPS Growth
- MCRB N/A
- TBI N/A
- EPS
- MCRB 10.22
- TBI N/A
- Revenue
- MCRB N/A
- TBI $1,534,863,000.00
- Revenue This Year
- MCRB N/A
- TBI $2.21
- Revenue Next Year
- MCRB N/A
- TBI $6.18
- P/E Ratio
- MCRB $1.74
- TBI N/A
- Revenue Growth
- MCRB N/A
- TBI N/A
- 52 Week Low
- MCRB $6.53
- TBI $3.45
- 52 Week High
- MCRB $24.67
- TBI $9.05
- Technical
- Relative Strength Index (RSI)
- MCRB 42.40
- TBI 47.79
- Support Level
- MCRB $17.63
- TBI $5.28
- Resistance Level
- MCRB $19.30
- TBI $5.63
- Average True Range (ATR)
- MCRB 1.12
- TBI 0.24
- MACD
- MCRB -0.29
- TBI 0.01
- Stochastic Oscillator
- MCRB 5.42
- TBI 54.49
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About TBI TrueBlue Inc.
TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.